Photo of Paolo Tarantino from X
Mar 4, 2024, 17:58
Paolo Tarantino: You don’t always need a fancy new drug to impact patients QoL
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:
”You don’t always need a fancy new drug to impact patients QoL. In the D-TORCH phase 3 trial, the use of topical diclofenac during capecitabine reduced the risk of G2-3 HFS (3.8% vs 15%, p=0.03) and of HFS-related dose reductions. Should be considered SoC.”
Read further.
Source: Paolo Tarantino/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19
Dec 21, 2024, 19:18
Dec 21, 2024, 18:59
Dec 21, 2024, 18:57